LABORATORIO FARMAC.ERFO (RK7) — Capital Reinvestment Ratio

Latest as of December 2023: 1.11x

LABORATORIO FARMAC.ERFO (RK7) has a Capital Reinvestment Ratio of 1.11x as of December 2023, meaning it reinvests 1% of its operating cash flow (€1.30 Million) in capital expenditures (€1.45 Million). See RK7 net asset quality index to measure how much of total assets are equity-financed.

Capital Reinvestment Ratio

1.11x
Capex / Operating Cash Flow

Operating Cash Flow

€1.30 Million
EUR

Capital Expenditures

€1.45 Million
EUR

Data as of

Dec 2023
Most recent filing

LABORATORIO FARMAC.ERFO Capital Reinvestment Ratio (2021–2023)

This chart tracks LABORATORIO FARMAC.ERFO's Capital Reinvestment Ratio across 3 annual periods. Check RK7 total capital reinvestment ratio to assess the company's total reinvestment commitment from operating cash flow.

Annual Capital Reinvestment Ratio for LABORATORIO FARMAC.ERFO (2021–2023)

Year-by-year Capital Reinvestment Ratio for LABORATORIO FARMAC.ERFO from 2021 to 2023. For live market cap and broader valuation context, see LABORATORIO FARMAC.ERFO (RK7) market capitalisation.

Year Reinvestment Ratio Operating CF (EUR) Capital Expenditures YoY Change
2023 1.11x €1.30 Million €1.45 Million ▼ -27.9%
2022 1.55x €761.80K €1.18 Million ▲ +1347.6%
2021 0.11x €2.27 Million €242.84K
Capital Reinvestment Ratio = ABS(Capital Expenditures) / Operating Cash Flow